Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: A review

Scandinavian Journal of Gastroenterology

Volumn 48, Issue 8, 2013, Pages 899-905

  Grunnet, Mie ^a   Mau Sorensen, Morten ^a   Brünner, Nils ^b  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Gastroduodenal clinical; Oncology clinical

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 1;

CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STOMACH CANCER;

ADENOCARCINOMA; HUMANS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 84880443007     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2013.812235     Document Type: Review

References (57)

1. Available athttp://globocan.iarc.fr.
2. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 2010;17:3077-9.
3. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastro esophageal cancer. N Engl J Med 2006;355:11-20.
4. Van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal and junctional cancer. N Engl J Med 2012;366:2074-84.
5. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma: an updated metaanalysis. Lancet Oncol 2011;12: 681-92.
6. Mosig RA, Dowling O, DiFeo A, Ramirez MC, Parker IC, Abe E, et al. Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Hum Mol Genet 2007;16:113-1123.
7. Vairaktaris E, Serefoglou Z, Yapijakis C, Vylliotis A, Nkenke E, Derka S, et al. High gene expression of matrix metalloproteinase-7 is associated with early stages of oral cancer. Anticancer Res 2007;27:459-64.
8. Chaudhuri R, McSharry C, Brady J, Donnelly I, Grierson C, McGuinness S, et al. Sputum MMP-12 in patients with chronic obstructive pulmonary disease and asthma: relationship to severity. J Allergy Clin Immunolol 2012;129:655-63.
9. Sandy J. A contentious issue finds some clarity: on the incident and complementary roles of aggrecanase and MMP activity in human joint aggrecanolysis. Osteo Cartil 2006;14:95-100.
10. Struglics A, Larsson S, Pratta MA, Kumar S, Lark MW, Lohmander LS. Human OA synovial fluid and joint cartilage contain both aggrecanase-and MMP aggrecan fragments. Osteo Cartil 2006;14:101-3.
11. Bao W, Fu HJ, Jia LT, Zhang Y, Li W, Jin BQ, et al. HER2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion. Arch Biochem Biophys 2010;499: 49-55.
12. Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W, Guillem JG. Elevated TIMP-1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1995;1:899-906.
13. Urbanski SJ, Edwards DR, Hershfield N, Huchcroft SA, Shaffer E, Sutherland L, et al. Expression pattern of MMPs and their inhibitors changes with the progression of human sporadic colorectal neoplasia. Diagn Mol Pathol 1993;2:81-9.
14. Avalos BR, Kaufman SE, Tomonaga M, Williams RE, Golde DW, Gasson JC. K562 cells produce and respond to human erythroid-potentating activity. Blood 1988;71:1720-5.
15. Agrez MV, Meldrum CJ, Sim AT, Aebersold RH, Clark IM, Cawston TE, et al. A fibroblast elngationfactor purified from colon carcinoma cells shares sequence identity with TIMP-1. Biochem Biophys Res Commun 1995;206:590-600.
16. Chesler L, Golde DW, Bersch N, Johnson MD. MMP inhibition and erythoid potentiation are indenpendent activities. Blood 1995;86:4506-15.
17. Jiang Y, Goldberg ID, Shi YE. Complex role of TIMPs in cancer. Oncogene 2002;21:2245-52.
18. Liu XV, Bernardo MM, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase 1 protectshuman breast apithelial cells against intrinsic apoptopic cell death via the focal adhesion kinase/PIK-3 and MAPK signaling pathway. Biol Chem 2003;278:40364-72.
19. Liu XV, Jung KK, Dong Z, Lee YJ, Roshy S, Sloane BF, et al. Tissue inhibitor of metalloproteinase 1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005;65:898-906.
20. Kessenbrock K, Placks V, Werb Z. Matrix metalloproteinases: regulators of the tumor micro inviroment. Cell 2010; 141:365-71.
21. Hayakawa T, Tanzawa K, Roshy S, Uchijima E, Iwata K. Growth-promoting activity of TIMP-1 for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992;298:29-32.
22. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A. In vitro supression of programmed cell death by TIMP-1. J Clin Invest 1998;102: 2002-10.
23. Bigelow RL, Williams BJ, Carroll JL, Davis LK, Cardelli JA. TIMP-1 overexpression promotes tumorigenesis of MDAMB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro. Breast Cancer Res Treat 2009;117:31-44.
24. Schrohl AS, Holten-Andersen NM, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, et al. Tumor tissue levels of TIMP-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004;10:2289-98.
25. Würtz SO, Schrol AS,Mouridsen H, Brunner N. TIMP-1 as a tumormarker in breastcancer. ACTA Oncol 2008;47:580-90.
26. Birgisson H, Nielsen HJ, Christensen IJ, Gemelius B, Brunner N. Preoperative plasma TIMP-1 is an independent indicator in patients with primary colorectal cancer: a prospective validation study. Eur J Cancer 2010;46: 3323-31.
27. Kemik O, Kemik AS, Sumer A, Dulger AC, Adas M, Begenik H, et al. Levelse of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer. WJG 2011;17:2109-12.
28. Mroczko B, Groblewska M, Lukaszewicz-Zajac M, Bandurski R, Kedra B, Szmitkowski M. Pretreatment serum and plasma levels of matrix metalloproteinase 9 and TIMP-1-in gastric cancer patients. Clin Chem Lab Med 2009;47: 1133-9.
29. Yoshikawa T, Cho H, Tsubutaya A, Kobayashi O. Impact of plasma tissue inhibitor of MMP-1 on longterm survival in patients with gastric cancer. Gastric Cancer 2009;12:31-6.
30. Wang CS, Wu TL, Tsao KC, Sun CF, et al. Serum TIMP-1-in gastric cancer patients: a potetial prognostic biomarker. Ann Clin Lab Sci 2006;36:23-30.
31. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, et al. Prognostic value of TIMP-1-in plasma of patients with gastric cancer. Cancer Lett 2000; 151:81-6.
32. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, et al. TIMP-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis. Cancer 1999;86:1929-35.
33. Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. BJC 1997;76:531-6.
34. Shim KN, Jung SA, Joo YH, Yoo K. Clinical significance of tissue levels of matrix metalloproteinases as tissue inhibitors of metalloproteinases in GC. J Gastroenterol 2007;42:120-8.
35. Kubben FJ, Sier CFM, Meijer MJW, van der Berg M, van der Reijden JJ, Griffioen G, et al. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer 2006;94:1035-40.
36. Kubben FJ, Sier CFM, Meijer MJW, van der Berg M, van der Reijden JJ, Griffioen G, et al. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer 2006;95:774-51.
37. Mroczko B, Groblewska M, Lukaszewicz-Zajac M, Czyzewska J, Gryko M, Szmitkowski M, et al. Expression of tissue inhibitors of metalloproteinase 1 (TIMP-1) in gastric cancer tissue. Folia Histochem Cytobiol 2009;47: 511-16.
38. de Mingo M, Morán A, Sánchez-Pernaute A, Iniesta P, Díez-Valladares L, Pérez-Aguirre E, et al. Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma. Hepatogastroenterology 2007;54:315-19.
39. Seo YS, Park JJ, Kim JH, Kim JY, Yeon JE, Kim JS, et al. Usefulness of MMP-9/TIMP-1 in predicting tumor recurrence in patients undergoing curative surgical resection for gastric carcinoma. Dig Dis Sci 2007;52:753-9.
40. YoshiwakaT,TsuburayaA,KobayashiO, SairenjiM,MiyagiY. Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as amarker for prognosis and recurrence in patients with gastric cancer. Gastric Cancer 2006;9:106-13.
41. Yoshiwaka T, Tsuburaya A, Kobayashi O, Sairenji M, motohashi H, Yanoma S, et al. Intratumoral concentrations of TIMP-1 in patients with GC, a new biomarker for invasion and its impact on survival. Cancer 2001;91:1739-44.
42. Joo YE, Seo KS, Kim HS, Rew HS, Park CS, Kim SJ. Expression of tissue inhibitors and metalloproteinases in Gastric Cancer. Dig Dis Sci 2000;45:114-21.
43. Zhang S, Zhu GY, Gao HY, Zhoa SP, Xue Y. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol 2003;9:899-904.
44. Holten-AndersenMN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Høyer-Hansen G, et al. Quantification of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999;80:1456-66.
45. Sorensen NM, Schrohl AS, Jensen V, Christensen IJ, Nielsen HJ, Brunner N. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumor tissue extracts from patients with primary colorectal cancer. Scand J Gastroenterol 2008;43:186-91.
46. Schrohl AS, Moeller V, Christensen IJ, Pantel K, Thomassen C, Brunner N. A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer. Tumour Biol 2008;29:181-7.
47. Vilmar AC, Santoni-Ruguie E, Soerensen JB. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 2010;21:1817-24.
48. Swain SM, Jeong J, Geier CE, Constantino JB, Pujol ER, Fehrenbacher L, et al. NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. Cancer Res 2009;69:75.
49. Okines AF, Cunningham D. Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer. Ther Adv Gastroenterol 2012;5:301-18.
50. Lievre A, Bachet JB, Boige V, Cavre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9.
51. Ejlertsen B, Jensen MB, Nielsen KV, Balslev E, Rasmussen BB, Willemoe G, et al. HER2, TOP2A and TIMP-1 and responsiveness to adjuvant antracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol 2010;28:984-90.
52. Sorensen NM, Bystrom P, Christensen IJ, Berglund Å, Nielsen HJ, Brunner N, et al. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-flourourasil and folinic acid. Clin Cancer Res 2007; 13:4117-22.
53. Frederiksen C, Qvortrup C, Christensen IJ, Glimelius B, Berglund Å, Jensen BV, et al. Plasma TIMP-1 levels and treatment outcome in patients treated with FOLFOX. Ann Oncol 2011;22:369-75.
54. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010:CD004064.
55. Okines A, VerhejiM, Allum W, Cunningham D, Cervantes A. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:v50-4.
56. NCCN guidelines. 2012. Available from: www.nccn.org/professionals/ physician-gls/pdf/gastric.pdf.
57. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor-MARKer prognostic studies. BJC 2005;93:387-91.